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The Breast Surgery theoretical and practical knowledge curriculum comprehensively describes the
knowledge and skills expected of a fully trained breast surgeon practicing in the European Union and Eu-
ropean Economic Area (EEA). It forms part of a rangeof factors that contribute to the deliveryof high quality
cancer care. It has been developed by a panel of experts from across Europe and has been validated by
professional breast surgery societies in Europe. The curriculummaps closely to the syllabus of the Union of
European Medical Specialists (UEMS) Breast Surgery Exam, the UK FRCS (breast specialist interest) cur-
riculum and other professional standards across Europe and globally (USA Society of Surgical Oncology,
SSO). It is envisioned that this will serve as the basis for breast surgery training, examination and accred-
itation across Europe to harmonise and raise standards as breast surgery develops as a separate discipline
from its parent specialties (general surgery, gynaecology, surgical oncology and plastic surgery).
The curriculum is not static but will be revised and updated by the curriculum development group of
the European Breast Surgical Oncology Certification group (BRESO) every 2 years.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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1.1. Training
Currently training across Europe in Breast Surgery is very het-
erogeneous with training hosted by general surgeons, gynaecolo-
gists and plastic surgeons. In general, training certification is
achieved after 4e6 years of residency training, which is usually of
mixed content, so for general surgery, residents will rotate through
colorectal, upper GI, endocrine, breast and often vascular surgery
with a substantial emergency surgery component. For gynaecology,
rotation will include urogynaecology, breast, oncology, obstetrics
etc as well as emergency work. Similarly for plastic surgery (rota-
tions will include trauma, breast reconstruction, skin cancer, soft
tissue sarcoma etc). Consequently at the time of certification, many
surgeons will have spent very little time doing breast surgery. In
some instances only a few months of residency training will be
spent in breast surgery but the surgeon will be able to undertake
breast surgery once certified.
Historically (40 years ago) breast surgery was quite simple, with
all women treated with mastectomy and axillary clearance with no
reconstruction and simple adjuvant therapy regimes. Modernbreast surgery is now highly complex from both a surgical and
oncological stand point and such limited training is not adequate
for modern breast practice. Ideally, breast surgery training for those
declaring a special interest during residency would be integrated at
a high level into the 4e6 years of residency. Residency training
programmes across Europe therefore need to recognise this need
and move towards this model, as has happened in the UK already.
However, this will take time and in the interim, BRESO proposes
that all surgeons practicing breast surgery in Europe should be
certified in breast surgery, by means of undertaking high level
training either within their residency (if available) or by means of
approved specialist fellowships. Certification will be based on the
following (see Fig. 1):
1. Acquistion of knowledge as demonstrated by passing approved
examinations.
2. Acquistion of practical skills as demonstrated by a certified
period of training in an approved breast unit and by review of a
signed log book.
3. Following completion of training and certification (as above) all
breast surgeons should engage with on going continuous pro-
fessional development (CPD) and apply for re-certification at
Fig. 1. Summary of measures to ensure high quality clinical practice for health care professionals.
T. Kovacs et al. / European Journal of Surgical Oncology 46 (2020) 717e736720intervals of 5 years by submission of proof of approved course
attendance. Such courses should be evidence based, free from
commercial bias and of high quality.
By these means BRESO will enhance and harmonise breast
surgery training and practice across Europe, improving standards
from the current very variable levels. Patients will also have a
means by which to reassure themselves about the provenance and
skills of their breast surgeon by using the BRESO searchable
directory of certified breast surgeons.
To do so, it is proposed that breast surgeons should have un-
dertaken aminimum of 2 years training in breast surgery (see Table
1 in the section below ‘Proposed temporal patterns of breast
training’). Twelve to 18 months of this may be in a breast unit
practicing intermediate level care, exposing trainees to wide local
excision (WLE), sentinel lymph node biopsy (SLNB), axillary clear-
ance and mastectomy, with good MDT working (tier 1 training
centres, basic training). This will enable trainees to develop basic
skills and a broad understanding of the subject. This may either be
during or after residency (certification) or a mixture of the 2.
However in addition, a period of high quality training in a specialist
breast center is required where higher level skills will be attained
such as oncoplastics, reconstruction (although not necessarily
practical expertise in all countries), research literacy, oncology and
genetics. These latter centres (tier 2 training centres, advanced level
skills) will need to be quality assured (for example EUSOMA
certified). This training may be post-residency (certification) in
most countries to allow full immersion in breast surgery without
the distraction of emergency surgery and other specialist subject
areas, unless such a specific post can be arranged during standard
residency training (as in the UK where Oncoplastic training is a
routine part of training for breast specialists). As a result, surgeons
will be expected to have acquired a minimum number of proced-
ures to the level required for post-residency practice, certified by a
recognised trainer.
Tier 2 training centres should be nominated and approved as
such by BRESO. Tier 2 will be similar in standard to EUSOMA cer-
tification but less proscriptive and we envisage that these will be
large teaching hospitals with a minimum of 250 cancers per year, at
least 3 specialist breast surgeons, a fully constituted MDT, access to
training in genetics, pathology, imaging and reconstruction. Tier 1
centres will be smaller centres, with at least 150 cancers per year,access to MDT working but may not have access to all reconstruc-
tion options or genetics clinics. It is hoped that tier 2 centres will
offer specific breast surgery fellowships to offer such training and
the BRESO website will maintain a database of such fellowships,
searchable by country and language.
The candidate will have to demonstrate their practical skills by
means of a certified log book and evidence of ability to undertake
key procedures to a good standard (axillary clearance (ANC), level 1
and 2 oncoplastic surgery (OCBS), wide local excision (WLE),
mastectomy (Mx) and skin and nipple sparing mastectomy (SSM/
NSM) for example). They will also be expected to demonstrate they
have attained knowledge in breast cancer management and more
in depth expertise in surgical management, as set out in the
knowledge curriculum (which will be attested to by the passing of
the UEMS European Board of Surgery Qualification (EBSQ) in Breast
Surgery exam or holding an approved higher degree or certificate of
competence, in addition to attendance at certified/approved cour-
ses and attendance at a minimum of 1 international breast
congress).
There are 3 elements contributing to the acquisition of training.
Theoretical knowledge acquisition, practical skills acquisition (and
certification processes relating to the above) and accreditation of
tier 2 centres/fellowships which provide training of adequate
quality to meet the above needs. In the post-certification period,
maintaining skills and knowledge is important and systems must
be in place to mandate and certify that breast surgeons keep up to
date in this rapidly progressing field.1.2. Theoretical knowledge
The knowledge curriculum contained in this document has been
developed to set out the required levels of theoretical knowledge a
certified surgeonmust possess. This will include both knowledge of
facts, the ability to critically apply this knowledge in the clinical
setting and the ability to assimilate and critically appraise new
knowledge as it is produced by new trials. The knowledge curric-
ulum will serve as the basis for courses, training programmes and
examinations linked to certification and will be updated every 2
years.
The knowledge curriculumwill be described in terms of 3 levels,
a basic level, likely to be acquired during the tier 1 training period
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tier 2 training and optional specialist knowledge (Specialist: S) for
example detailed knowledge of technical aspects of
reconstruction).
All residents/fellows will be required to demonstrate detailed
knowledge of the basic (B) and advanced (A) curriculum but the
specialist knowledge (S) requirements may be used to tailor
training to variations in national requirements where some coun-
tries do not require breast surgeons to be able to reconstruct,
whereas others do. This will allow EU member states to engage
fully with the programme with some ability to tailor requirements.
Similarly the practical skills requirements may be tailored
depending on national and speciality specific requirements (for
example whilst all surgeons will be expected to be competent in
axillary clearance, and level 1 and 2 oncoplastic surgery, whole
breast reconstruction and pedicled, free and perforator flaps may
only be appropriate for some countries or for plastic surgeons).
The knowledge curriculumwill be provided within training and
by attending courses and congresses and tested by examination.
The curriculum is based on the UEMS EBSQ in Breast Surgery Exam
syllabus and the passing of the UEMS exam will confirm adequate
knowledge for the purpose of certification. Other breast examina-
tions may also apply to serve a similar purpose, such as the Uni-
versity of East Anglia (UEA) MSc in Breast Surgery, the ESO CCB
Certificate of Competence in Breast Cancer and the FRCS (Breast
subspeciality interest) in the UK. Courses which provide the
knowledge curriculumwill include a requirement to attend at least
2 International evidence based congresses, focussed on breast
diseases (such as San Antonio, St. Gallen, EBCC or similar).
There will also be a requirement to attend training courses,
which may apply to be BRESO certified for this purpose, such as the
ESSO Breast courses (advanced, oncoplastic), the ESO certificate
course or masterclass, the University of East Anglia (UEA) Masters
course and others. A small administration fee will be charged toTable 1
Proposed temporal patterns of breast training.
Residency (usually 4e6 years in most European Countries) Post residency
Year 1 2 3 4 5 6 7
General training General training General training General training Br1 Br2
General training Br1 General training General training General training Br2
Br1 General training General training General training Br2
General training General training General training General training General training Br1 Br2
Tier 1 breast training for 12 months could take place at any time during standard general training (from years 1e5) and may even be split into smaller blocks. If not present
during standard training it must be part of a fellowship after completion of general training. It is shown as in years 1, 2 or 5 in the examples above but this is not exclusive and
other permutations are possible.
Tier 2 breast training should take place towards the end of training, either as part of standard training in year 5 or as a fellowship after completion of general training.
General Training relates to standard residency in either general surgery, gynaecology or plastic surgery.
Br1: Basic Training in a Tier 1 unit.
Br2: Advanced (þ/-specialist) fellowship training in a Tier 2 unit.course providers for approval (‘approved by BRESO’) after which
they will be listed on the searchable BRESO website. Courses may
be in English or other languages.1.3. Practical skills
Acquisition of skills during training needs to be both numeri-
cally and qualitatively adequate for certification. It is envisaged that
development of basic skills will be acquired during time spent in a
tier 1 center (core biopsy, mammography interpretation, commu-
nication skills, diagnostic biopsy, simple mastectomy, level 1
oncoplastic WLE, SLNB and ALND).
Level 2 skills will include skin and nipple sparing mastectomy,
level 2 oncoplastic skills, lipomodelling, implant management andreconstruction decision making, selection criteria and risks and
benefits and complex oncological and genetic decision making and
management. For those in National systems where reconstruction
is not the role of the breast surgeon, but performed in conjunction
with plastic surgery colleagues, observation of reconstruction of
various types must be demonstrated but need not be performed
personally.
All breast surgeons must have a theoretical understanding of
breast reconstruction in order to be able to offer women appro-
priate treatment options. For those from national systems where
reconstruction is a core role of the breast surgeon, operative
numbers and quality assessments must be demonstrated. In this
way the skills set may be tailored to national requirements/
systems.
Training requirements will therefore be designated as Tier 1,
Tier 2 or Specialised (determined by National agreement). Systems
for certification of practical competencies will be developed by the
BRESO skills working group and may involve designated trainers
signing off cases or an on line system of log book validation.1.4. Tier 2 centre/fellowship approval
An integral part of this process will be certification of centres as
tier 2 training centres. Again, a small fee (varied according to the
income of the host country to ensure it is affordable) will be
charged to cover the cost of accreditation and centres will be listed
in a searchable list on the website. In addition, formal tier 2 and
specialist fellowships will be listed on the BRESO website if
available.1.5. Proposed temporal patterns of breast training1.6. Continuing professional development
BRESO also proposes that for all practicing breast surgeons there
should be some form of light touch re-certification at intervals of 5
years. This will include providing documentation that they have
attended high quality oncology and oncoplastic courses that are
free from commercial bias and have evidence based content.2. Knowledge curriculum
The speciality of Breast Surgery requires different levels of
knowledge at different stages during surgical training. Basic level
knowledge (B) is appropriate for surgeons during their general
training in general surgery, gynaecology or plastic surgery and is
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this discipline. Breast surgery is regarded as a specialist discipline
within general surgery or gynaecology and all surgeons treating
breast cancer should have advanced level skills and knowledge (A).
It is recognised that some specialist-level knowledge and skills will
only be provided by specialists in tertiary centres or by plastic
surgeons (S). Throughout this curriculum knowledge is categorised
into these 3 levels to guide training provision. Examinations
approved by BRESO will test knowledge to advanced level with
some specialist level knowledge. The knowledge curriculum is the
responsibility of the BRESO theoretical knowledge working group
and will be updated every 2 years.
3. Basic science
3.1. Physiology and development of the breast
❖ Development of the breast (A), proliferation during pregnancy
(B), involution after lactation (B), involution during menopause
and the hormonal stimuli that trigger these changes and how
these may be affected by drugs, diseases, physiological variation
(B).
❖ Abnormalities in breast development including hypoplasia (A)
(including Poland's anomaly), hyperplasia, tubular breast,
accessory breasts and nipples (A).
❖ The physiology of the male breast, its developmental stages,
hormonal regulation and developmental variation (gynaeco-
mastia) (A).
❖ Investigative work-up and management strategies for develop-
mental and physiological abnormalities must be understood (A)3.2. Surgical anatomy of the breast and axilla
❖ Muscles and fascia of the thoracic wall and axillary region (B)
❖ Blood supply to the breast, overlying skin and nipple-areola
complex as well as the vascular anatomy of the axilla (B)
❖ Neural anatomy of the breast, thoracic wall, axillary area and
upper arm (B)
❖ Lymphatic drainage patterns to the ipsilateral axilla, sub- and
supraclavicular nodal basins, internal mammary nodal basin
and contralateral axilla (B)
❖ Relevant surgical and vascular anatomy of common flaps used in
breast reconstructive surgery (A,S)
❖ Anatomic variants and variants induced by treatments (such as
the impact on vascular perfusion following radiotherapy, pre-
vious surgery and surgical scars) and how these may be
managed clinically (A)3.3. Pharmacology relevant to breast disease
❖ The endocrinology of the breast: influences of oestrogen (the
oral contraceptive or menopausal hormone therapy (MHT)),
progesterone, testosterone, oxytocin and prolactin (B)
❖ Impact of a range of drugs on breast function: drugs causing
gynaecomastia, hypertrophy, secretion (A). Drugs causing breast
development in gender reassignment (S).
❖ Drugs relevant to breast cancer: SERMS (B), aromatase in-
hibitors (B), fulvestrant (A), oestrogen (B), progestogens (B),
GnRH agonists (A), chemotherapy agents (A) and GCSF (A),
biological agents (trastuzumab, pertuzumab, lapatinib, ner-
atinib TDM-1, CD4/6 inhibitors, PARP inhibitors, denosumab)
(A), bisphosphonates (B), immune modulators (S).❖ Drugs relevant to the treatment of breast pain: tamoxifen (A),
danazol (B), GnRH agonists (A).
❖ Other: Analgesics for use in acute and chronic pain settings (B),
antiemetics for the management of post-surgical nausea (B),
antibiotics for use in the prophylactic setting in surgery and for
the treatment of infections (B), low molecular weight heparins
for DVT prevention in the perioperative period (B), local
anaesthetic agents for use in the perioperative period for local
and regional blocks (B).3.4. Microbiology
❖ Common microorganisms causing breast pathology (B)
❖ Preferred antibiotics for common breast infections (B)
❖ Aetiology of breast sepsis (B)
❖ Management of breast sepsis (B)
❖ Signs and symptoms of severe sepsis (B)
❖ Management of severe sepsis including septic shock(B)3.5. Epidemiology of breast pathologies
❖ Influence of age of menarche, pregnancies, lactation, meno-
pause, hormonal treatments on disease risk (B)
❖ Family history (assess pedigrees, document and assess breast
cancer risk factors and BRCA gene carrier risk status) (A)
❖ Genetics of breast cancer (high and moderate risk genes, single
nucleotide polymorphisms SNPs) (A)
❖ Risk of previous breast conditions and procedures (B)
❖ Impacts of age, co-morbidities, medications, frailty on prognosis
and risks of over and under treatment (B)
❖ Lifestyle risk factors for breast disease (e.g. smoking and risk of
periductal mastitis; obesity, alcohol, exercise, oral contracep-
tives, menopausal hormone therapy (MHT), immunosuppres-
sive therapy as risk factors for breast cancer) (B)
4. Diagnostic methods
4.1. Clinical examination
❖ Symptoms of benign or malignant breast diseases or conditions
(B)
❖ Symptoms suggestive of nodal or distant metastases (B). Ability
to perform an adequate examination of the breasts, axillary and
other regional nodal basins (B)
❖ Understanding of the common signs and examination findings
suggesting a range of breast pathologies and how these should
be further investigated (B).
❖ Understanding the other clinical findings which may be linked
to breast pathologies (evidence of metastatic disease, develop-
ment of secondary sex characteristics (or lack thereof), physical
signs that may link to gynaecomastia in the male (testicular
abnormalities, hepatic dysfunction, obesity) (B)
❖ How to examine and assess a womanwith breast augmentation,
cosmetic or reconstructive breast surgery (A).4.2. Breast (and related) imaging techniques
4.2.1. Mammography
❖ Age appropriate indications for mammography (B)
❖ Sensitivity and specificity and factors influencing these (A)
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contrast enhanced mammographic techniques (A).
❖ Different views (craniocaudal and mediolateral oblique) and the
role of compression views (A).
❖ Understanding of how to interpret standard mammographic
abnormalities and the imaging features typical of benign or
malignant pathology (B, A).
❖ Mammographic limitations in certain groups such as young
females, females with dense breasts, lobular cancer and in the
presence of implants (A)
❖ Eklund technique (Eklund GW et al. Improved imaging of the
augmented breast. AJR Am J Roentgenol. 1988; 151 (3): 469e73)
to optimise mammography in the presence of implants (A).
❖ Role of mammography in screening programmes (B)
❖ Role of mammography in stereotactic biopsies and different
localization techniques (B)
❖ BI-RADS classification of malignancy (BI-RADSM1-5) and breast
density (BI-RADS A-D) (A)
❖ Role of mammographic examination of operative specimens (A)4.2.2. Breast ultrasound
❖ Age appropriate indications (B)
❖ Intraoperative localization techniques (B)
❖ Sensitivity and specificity, factors influencing sensitivity and
specificity (A)
❖ Ultrasound guided breast biopsies, how performed, indications
and contraindications (B)
❖ Understanding how to interpret standard ultrasound abnor-
malities and the imaging features typical of benign or malignant
pathology (B, A)
❖ Role of Automated Breast Ultrasound (ABUS) (A)
❖ Stavros' criteria [Stavros AT et al. Radiology.1995 Jul;
196(1):123e34] for benign lesions (A)4.2.3. MRI
❖ How performed, indications, limitations and contraindications,
sensitivity and specificity, factors influencing sensitivity and
specificity in invasive cancer and in DCIS (A,B)
❖ Role in surveillance of high risk women (A)
❖ Role when contradictory findings in triple assessment (A)
❖ Role in determining response in patients with neoadjuvant
treatment (A)
❖ Role in detecting contralateral cancer (A)
❖ Role in the assessment of lobular cancer, multifocal cancer and
dense breasts (A)
❖ Role when planning breast conserving surgery (B, A)
❖ The limited influence of pre-op. MRI on local recurrence rates
(A)
❖ Management of lesions detected only on MRI (MRI localised
biopsy) (A)
❖ Role in management of the occult breast primary (A)
❖ The benefits and risks of MRI: highly sensitive but risk of ‘un-
necessary’ biopsies/mastectomies (A)
❖ Role in assessment of operability in locally advanced or recur-
rent disease of the breast and axilla (A)
❖ Use of MRI of areas outside the breast in the further evaluation
of equivocal staging test results to diagnose liver, bone, CNS/
spine metastases (A)
❖ Ability to interpret MRI imaging (obvious malignancy, obvious
nodal disease, implant rupture (intra and extra capsular
rupture) (A)4.2.4. Staging CT
❖ Indications and contraindication for CT staging (B)
❖ Able to interpret simple CT abnormalities (liver, lung or obvious
bone metastases) (A)
❖ Value of and indications and contraindications for the use of IV
contrast (B)
❖ Use of CT angiography in planning free flaps (A)
❖ Indications for and value of PET CT (B)4.2.5. Isotope bone scan
❖ Understanding how isotope bone scan works (B)
❖ Indications and contraindications for scanning (B)
❖ Able to interpret simple abnormalities (A)
❖ Follow on investigation in equivocal cases (e.g. CT scan or MRI of
the bone when needed and rarely, use of bone biopsy) (A)4.2.6. Dual emission X ray absorptiometry (DEXA) bone density
scan
❖ Use in monitoring bone density in women on aromatase in-
hibitor (AI) therapy (B)
❖ Indications for DEXA scanning (B)
❖ Technical aspects of how this type of scan works and how it
differs from an isotope bone scan (B)
❖ Understanding interpretation of bone density reports and
scoring (B)
❖ Understanding of management of women with osteopenia and
osteoporosis induced by ovarian function suppression, oopho-
rectomy or in the presence of AI therapy (A)4.2.7. PET_CT
❖ Use in staging in advanced breast cancer and in the investigation
of axillary nodal disease of unknown primary (A)4.2.8. Percutaneous needle biopsies
❖ Fine needle aspiration cytology e how performed, indications
and contraindications, sensitivity and specificity, factors influ-
encing sensitivity and specificity. Awareness that it is less sen-
sitive and specific than core biopsy for the breast primary but
has value in the assessment of lymph nodes (B)
❖ Core needle biopsy-how performed, indications and contrain-
dications, sensitivity and specificity, factors influencing sensi-
tivity and specificity (B)
❖ Vacuum assisted biopsy and vacuum assisted excision-how
performed, indications and contraindications, sensitivity and
specificity, factors influencing sensitivity and specificity (A)
4.3. Breast (and related) pathology
❖ The morphologic spectrum of normal breast tissue (juvenile/
prepubertal breast, lactating breast, normal premenopausal
breast, involution patterns, aberrations of normal development
and involution (ANDIs), minimal changes, fibrocystic changes
(B)
❖ Interpretation of preoperative diagnostic categories by fine-
needle aspiration or discharge cytology (C1eC5) and core nee-
dle biopsy (B1eB5) (B)
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circumscribed masses, spiculate masses, parenchymal asym-
metry, microcalcification; Lack of correlation or correlations
requiring further surgery (A)
❖ Subgross morphology of breast tumours, including the extent
(measure of the tumour involved breast area/volume), the
focality/distribution (unifocal, multifocal, diffuse), the size
(invasive/prognostic tumour size) of the lesions (Tot T et al. The
subgross morphology of breast carcinomas: a single-institution
series of 2033 consecutive cases documented in large-format
histology slides. Virchows Arch. 2019 Aug 13). (A)
❖ Specimen fixation, cold ischaemic time, pre-analytic conditions
with influence on histopathological assessment prognostic and
predictive markers; specimen of collection for tumour banking
(A)
❖ Value of specimen mammography, both intraoperatively to
ensure specimen identification and margin optimisation but
also by the pathologist in disease localization and extent
assessment (A)
5. Breast cancer epidemiology and natural history
5.1. Epidemiology
5.1.1. Incidence and mortality
❖ Rising incidence in the western world (B)
❖ Impact of aging populations (B)
❖ Impact of screening (B)
❖ Mortality trends and effect of earlier diagnosis, treatment
impact (B)5.1.2. Breast cancer risk factors: non-hereditary
❖ Age (B)
❖ Ethnic Group (B)
❖ Gender (B)
❖ Alcohol (B)
❖ Obesity (B)
❖ Dietary factors (B)
❖ Exogenous oestrogen use (menopausal hormone replacement
therapy, oral contraceptive, IVF drugs, antioestrogens/SERMs
and AIs) (B)
❖ Sedentary lifestyle (B)
❖ Mantle radiotherapy (B)
❖ Proliferative, non-high risk lesions of the breast (fibroadenoma,
sclerosing adenosis, intaductal papilloma etc) (B)
❖ High risk lesions (lobular neoplasia in situ, radial scar (risk of
concomitant cancer), atypical ductal hyperplasia, columnar cell
hyperplasia) (B)5.1.3. Genetic predisposition: breast cancer risk and risk of other
malignancies
❖ High risk hereditary breast cancer risk syndromes: BRCA1 (B),
BRCA 2 (B), tp53 mutation (Li-Fraumeni syndrome) (A), Cow-
den's syndrome (A), Peutz-Jegher's syndrome (A), Hereditary
diffuse gastric cancer syndrome, (A), PALB2 (A).
❖ Risk counselling and risk management strategies for the unaf-
fected (non-cancer) gene carrier and cancer management stra-
tegies for the gene carriers already diagnosed with cancer (A).
❖ Indications for gene testing and pre-test counselling (A).❖ Moderate risk, germ line mutations: Ataxia-telangiectasia
mutated (ATM) (A), CHEK-2 (A), PALB2 (A) and awareness of
rapid rise in number of more recently identified clinically
important mutations (A).
❖ Weaker hereditary factors such as low penetrance genes and
single nucleotide polymorphisms (S).
❖ Genetic consortia programmes to accrue large cohorts globally
to refine risk prediction for these newer genetic factors (A).
❖ The rise of commercial polygene arrays to risk assess and the
potential risks and benefits of their use (A).
❖ Variants of unknown significance and how to manage these
individuals (S)5.1.4. Breast cancer risk estimation for healthy women with a
family history
❖ Pedigree assessment (A, B)
❖ Tyrer-Cuzick (IBIS II) on line risk assessment tool (A)
❖ BOADICEA risk assessment tool (A, S)5.1.5. Management of high and moderate familial breast cancer risk
women
❖ Surveillancewith breast imaging: age appropriate strategies and
evidence of efficacy (MRI, MMG, US) (A)
❖ Risk reducing surgery: breast and ovary (A). Magnitude of risk
reduction (A), impact on survival in bilateral non-cancer cases
(A) and unilateral contralateral RRM in women with cancer (A),
psychological impacts (A), techniques (skin or nipple sparing)
(A), risk of occult malignancy (A).
❖ Chemoprevention (A): SERMS (tamoxifen, raloxifene), aroma-
tase inhibitors (exemestane and anastrozole), trial evidence of
benefit, indications for and contraindications to, age of use,
duration of use. Adverse events.5.2. Breast cancer screening
❖ Theoretical underpinnings of all screening programmes (WHO
Principles, 1968, updated in 2008) (B)
❖ Quality requirements (EUSOMA), EU standards and own Na-
tional specific quality measures and provision (B)
❖ Compliance rates for effective screening (A)
❖ Positive and negative influences of screening on breast cancer
incidence, mortality, morbidity and survival rates (A)
❖ Factors influencing sensitivity and specificity (A)
❖ Validated screening tools (analogue and digital mammography,
MRI) (B)
❖ Newer screening modalities (ABUS, tomosynthesis) (A)
❖ Targeted screening/surveillance in higher risk subgroups: fa-
milial risk, genomic risk, previous disease and treatment such as
mantle radiotherapy (A)
❖ False positive findings and over diagnosis and their adverse
impacts (B)
❖ Surgical and diagnostic techniques relevant to screening (vac-
uum assisted biopsy, localization techniques for surgery) (B, A)
❖ Management of screen detected borderline and premalignant
lesions (radial scar, DCIS, atypias etc) (A)
❖ Screening age ranges and their justification (B)
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5.3.1. Basic concepts in cancer biology
❖ Cell kinetics, proliferation, apoptosis and the balance between
cell death and cell proliferation (A)
❖ Angiogenesis and lymphangiogenesis (A)
❖ Knowledge of key molecular pathways in breast cancer of
therapeutic significance (Her-2, ER) (A)
❖ Genome maintenance mechanisms to prevent cancer (A)
❖ Intercellular and intermolecular adhesion mechanisms and
signalling pathways (A)
❖ Immunological mechanisms that either prevent or promote
cancer growth and dissemination (A)
❖ Potential effects of surgery and surgery-related events on cancer
biology (e.g. angiogenesis) (A)5.3.2. Natural history, prognosis, prognostic and predictive factors
❖ Patterns and incidence rates of local, regional and distant
dissemination (B)
❖ Differences in dissemination patterns due to biological tumour
subtypes (A)
❖ Tumour and nodal stages (TNM Classification, version 8, January
2018) (B)
❖ Tumour grade (Elston and Ellis classification) (B)
❖ Ki-67 expression (A)
❖ Histological (morphological) subtypes of invasive cancer (B)
❖ Array based classification of Sorlie and Perou (luminal A, B, basal
etc) (A)
❖ Oestrogen and progesterone receptor expression (Allred, H
score) and clinical relevance (B)
❖ HER-2 (c-erb-b2) over-expression and clinical impact (B), In-
termediate cases (2þ) by IHC and HER-2 expression by FISH,
CISH (A)
❖ The role of “conventional” breast pathology (tumour diagnosis,
prognosis, specimen analysis, node analysis, neoadjuvant
response assessment) (B)
❖ Intraoperative assessment techniques (frozen section, OSNA,
imprint cytology for nodal staging, frozen section for margins)
(A)
❖ The role of Multi-Gene Assays in both prognostic and predictive
settings (costs, benefits and limitations) (A)
❖ Differences and similarities in tumour biology between sporadic
and hereditary breast cancer (A)
❖ The influence of circulating tumour cells on prognosis and the
new technique of ‘liquid biopsy’ (S)
❖ The risk of and risk factors for synchronous and metachronous
breast cancer (A)
❖ Prognostic Tools: For example: Nottingham Prognostic Index,
NHS PREDICT, MSKCC nomograms. Differences and applicability
(A)
❖ The role of the immune system in tumour development, pro-
gression and regression; immune system related predictors of
the response to treatment (adjuvant, neoadjuvant, immune-
oncologic) e tumour infiltrating lymphocytes (A)5.4. Breast cancer: staging
❖ Clinical staging of the primary tumour and the axilla and its
accuracy (B)
❖ Preoperative axillary staging by ultrasound (sensitivity and
specificity) (B)❖ Surgical staging of the axilla - indications, methods, sensitivity,
advantages, disadvantages (B)
❖ CT-scan: how performed, the indications, sensitivity and speci-
ficity (B)
❖ PET- CT scan: how performed, the indications, sensitivity and
specificity (B)
❖ Isotope bone-scan: how performed, indications, sensitivity and
specificity (B)
❖ Clinical and pathological TNM-classification (version 8)
including post-neoadjuvant designation (B)
❖ Stage migration due to improved staging accuracy, (e.g. detect-
ing micrometastases in sentinel lymph node biopsy) (A)
❖ Post neoadjuvant response categorisation systems such as re-
sidual cancer burden (A)5.5. The role of the multidisciplinary team (MDT) in breast cancer
❖ Multimodality treatment of breast cancer (B)
❖ Ideal composition of the MDT (B)
❖ Responsibilities and tasks distribution among the MDT
members
❖ Defining local protocols and workflows
❖ Understanding the role of the MDT in data flow
❖ Educational and training role of the MDT (B)
❖ Audit and governance role of the MDT (B)
❖ Costs of the MDT (A)
❖ EUSOMA guidelines regarding multidisciplinary teams and
meetings (A)
6. Breast cancer surgery
6.1. Conservation surgery for breast Cancer/DCIS
6.1.1. Localization of impalpable lesions (benign, borderline or
malignant)
❖ Guide wire (B)
❖ ROLL (radioguided occult lesion localization) (A)
❖ RSL (radioguided seed localization) (A)
❖ Magnetic seed or tracer localization (A)
❖ Guidance by intraoperative ultrasound (A)
❖ Advantages and disadvantages of various localization methods
(A)
❖ The role of specimen radiography (B)
❖ Role and value of variety of margin assessment devices and
techniques (A)6.1.2. Conservative surgical treatment of (DCIS and invasive)
disease within the breast
❖ Indications and contraindications for breast conservation (A, B)
❖ The location, size and the multifocality/multicentricity of the
tumour (A)
❖ The size and the shape of the breast, including assessment of
degree of ptosis (A)
❖ The predicted aesthetic outcome after breast conservation (A)
❖ The role of neoadjuvant systemic treatment in facilitating breast
conservation, including indications and contraindications as
well as predicting and evaluating the response (A)
❖ Patient preference (B)
❖ Medical contraindications for radiotherapy: previous RT, heavy
smoker/COPD, dementia, confusion and agitation, positioning
limitations (B)
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❖ Volume displacement versus volume replacement: techniques
and indications, risks (A)
❖ Level I and level II oncoplastic techniques in breast conservation.
Aware of contraindication and indications for oncoplasty,
different techniques by disease quadrant (atlas of technique by
K Clough), risks of oncoplastic surgery (A)
❖ Management of cavity (marking with clips), pathological docu-
mentation and specimen marking (B)
❖ The need for contralateral surgery for symmetry: techniques,
indications, contraindication, timing, impact of radiotherapy (A)6.1.4. Breast conservation
❖ The influence of margin width on local recurrences (B)
❖ The role of cavity shavings to ensure sufficient margins (A)
❖ Risk of local recurrence and patient and tumour stage, margin
assessment and biology related risk factors for local recurrence
after breast conservation (A)
❖ The influence of breast radiotherapy on local recurrences (B)
❖ Role of boost radiotherapy and need to enable radiotherapy
targeting including impact on local recurrence rates, indications,
cosmetic impacts (A)
❖ The influence of adjuvant systemic treatment on local re-
currences (A)
❖ Treatment of local recurrences after breast conservation
including indications for re-do conservation surgery (A)
❖ The influence of local recurrences on survival (A)
❖ Nodal staging in patients with local recurrence after breast
conservation and negative sentinel node biopsy (A)6.1.5. Methods to correct poor aesthetic outcome after breast
conservation
❖ Free fat grafting (S)
❖ Partial reconstruction (pedicle and perforator flaps) (S)
❖ The aesthetic outcomes after such procedures (S)
❖ Oncological safety of these techniques (S)6.2. Mastectomy
6.2.1. Mastectomy indications and types
❖ Indications for mastectomy (absolute and relative) (B)
❖ Immediate and delayed reconstruction-indications and contra-
indications (A).
❖ Nipple-areola complex sparing mastectomy, indications, con-
traindications. Risk of and risk factors for complications (A)
❖ The risk of nipple involvement, the role of frozen section from
central ducts (A)
❖ Evidence from trials comparing mastectomy and breast con-
servation (A)
❖ Psychological impacts of mastectomy (A, S)
❖ Bilateral risk reducing mastectomy (A)
❖ Contralateral risk reducing mastectomy (indications, outcomes)
(A)
❖ Surgical complications of mastectomy and how tomanage them
(B).6.2.2. Local recurrence after mastectomy
❖ The risk of and risk factors for local recurrences (A)
❖ The influence of radiotherapy on local recurrences (B)
❖ Presentations of local recurrence (B)
❖ The influence of adjuvant systemic treatment on local re-
currences (A)
❖ Treatment of local recurrences after mastectomy including
reconstructive methods in extensive recurrences (A)
❖ The influence of local recurrences on survival (A)6.2.3. Breast reconstruction
❖ Implant reconstructions e indications, contraindications, com-
plications, costs (A)
❖ Long-term sequelae of implant reconstruction: need for revision
surgery (A), capsule formation (A), extrusion (B), infection (B),
leakage (B), rupture (B), BIA-ALCL (A).
❖ Interactions and potential interactions of reconstructive surgery
and oncology treatments (chemotherapy, radiotherapy, trastu-
zumab) (A)
❖ Acellular dermal matrices and synthetic meshesdbiology, in-
dications, contraindications, complications (A)
❖ Pedicle and perforator flap reconstructions (latissimus dorsi,
LICAP, TDAP etc)etheir indications, contraindications, compli-
cations, costs (S)
❖ Micro-vascular flaps e (DIEP, TRAM, SGAP, IGAP, TUG), their
indications, contraindications, complications, costs (S).
❖ Factors influencing aesthetic outcome after breast reconstruc-
tion (S)
❖ Oncological safety of immediate and delayed reconstruction (A)
❖ Influence of reconstruction on quality of life (A)
❖ Surgical complications of reconstructive surgery (short, medium
and long term), (A)7. Axillary surgery
7.1. Sentinel node biopsy (SNB) in invasive cancer, DCIS and Paget's
disease of the breast
❖ The sentinel node concept (B)
❖ The indications and contraindications for SNB (B)
❖ Sensitivity of SNB and factors influencing the sensitivity, (B)
❖ The role and outcome of SNB in patients with local recurrence
and previous axillary surgery (A)
❖ The advantages, disadvantages and outcome of SNB before
neoadjuvant systemic treatment (A)
❖ The advantages, disadvantages and outcome of SNB after neo-
adjuvant systemic treatment (A)
❖ The role of SNB outside the axilla, like in the internal mammary
nodal basin (A)
❖ Radioisotope localization-advantages and disadvantages (B)
❖ Other localization methods (magnetic, indocyanine green) (A)
❖ Blue dye - advantages and disadvantages (B)
❖ The role of preoperative lymphoscintigraphy (conventional and
SPECT) (A)
❖ The role of and methods for intraoperative assessment of
sentinel node metastases (A)
❖ The histopathological methods in assessment of the sentinel
node metastases (A)
❖ Other methods (such as OSNA) in assessment of the sentinel
node metastases (A)
❖ Classification of tumour positive sentinel node findings (A)
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vation, axillary radiotherapy, axillary lymph node dissection) (B,
A)
❖ The advantages and limitations of nomograms predicting
further nodal involvement (B,A)
❖ Morbidity after sole SNB, and after further treatment of axilla
with axillary radiotherapy and axillary lymph node dissection
(B)
❖ Impact of isolated tumour cells, micro and macrometastases in
prognosis and further axillary management (B)7.2. Axillary lymph node dissection (ALND) in invasive cancer
❖ The indications and contraindications of ALND (B)
❖ Anatomy of the axilla (B)
❖ Advantages and morbidity of ALND in patients with axillary
metastases (early, intermediate and late) (B)
❖ Alternative to ALND in low volume/low risk axillary disease (B)
❖ The role of preserving intercostobrachial nerves (A)
❖ Berg levels of the extent of ALND (B)
❖ Risk of lymphoedema, its classification and management (A)7.3. Regional recurrences after axillary surgery (SNB, ALND)
❖ The risk of and risk factors for regional recurrences (B)
❖ The influence of radiotherapy on regional recurrences (B)
❖ The influence of adjuvant systemic treatment on regional re-
currences (A)
❖ Treatment of regional recurrences after SNB and ALND (A)
❖ The influence of regional recurrences on survival (A)
❖ Assessment of operability (US/CT/MRI scan) and indicators for
inoperability (A)7.4. Axillary metastases with unknown primary
❖ Differential diagnosis and how to distinguish between axillary
metastases from breast cancer and other malignancies (for
example melanoma) (A)
❖ The role of imaging modalities, such as breast MRI (B)
❖ The role of pathology (A)
❖ The role of CT and PET-CT scans to rule out distant disease or
other malignancy than breast cancer (B)
❖ Treatment (surgery, radiotherapy, systemic) (A)7.5. Axillary management in the neoadjuvant setting
❖ Targeted axillary dissection (techniques, sensitivity, specificity,
trials) (A)
❖ Use of different TAD markers (clips, iodine seeds, magnetic
marker systems, ink marking) (A)
❖ Upfront SLND for the clinically negative axillary versus post NAC
SLND (accuracy, sensitivity and specificity, trials) (A)
8. Adjuvant systemic therapies in breast cancer
8.1. Systemic chemotherapy
❖ Agents and regimens used in the adjuvant setting, including
common side effects and contraindications (e.g. hair loss, mye-
losuppression, cardiac toxicity with some regimes) (A)
❖ Indications and contraindications (B)❖ Internet based tools used to help in decision making (such as
PREDICT), advantages, disadvantages of each (A)
❖ Multigene assays used to help for prognosis and decision-
making (such as OncotypeDX, Mammaprint, PAM-50, Endo-
predict etc.) (A)
❖ Influence on local and regional recurrences and survival (B)
❖ Emerging data about adjuvant therapies after neoadjuvant
therapy poor response (A)
❖ Cellular/molecular targets for chemotherapy, endocrine and
targeted treatments, and their mechanisms (A)
❖ Common side effects and their management (A)
❖ Interaction with surgery, for example effect on wound healing,
surgical delay before chemotherapy starts if surgical complica-
tions, risk of infections, risk of thrombosis (B)
❖ Local and regional recurrences and survival after adjuvant sys-
temic chemotherapy (A)
❖ Agents in trials pipelines (S)8.2. Systemic hormonal therapy
❖ Agents used (tamoxifen, aromatase inhibitors), duration of use
(5 years, 10 years), strategies of AIs use (upfront, switching, late
extended) (A)
❖ Indications and contraindications (B)
❖ Tools used to help in decision making (such as PREDICT), (A)
❖ Influence on local and regional recurrences and survival (B)
❖ Cellular/molecular targets for agents (the ER, aromatase en-
zymes) (A)
❖ Common side effects and their management (acute and long
term) (A)
❖ Interaction with surgery, for example risk of thrombosis with
tamoxifen (B)
❖ Bone density monitoring protocols and management in women
on AIs (B)
❖ Use of ovarian suppression therapy to augment hormone
blockage in certain subgroups: indications, evidence and
adverse effects (e.g SOFT and TEXT trials). (A)8.3. Adjuvant bisphosphonates
❖ Agents used, including route of administration and duration,
indications and contraindications (A).
❖ Common and rare but significant (e.g. jaw necrosis) side effects
(A)
❖ Evidence for benefit in the adjuvant setting (A)
❖ Impact on survival and rates of metastatic recurrence (A)8.4. Adjuvant molecular targeted therapies
❖ Mechanism of action and receptor pathway and interactions (A)
❖ Agents: trastuzumab, pertuzumab, lapatinib, TDM-1, neratinib
(A)
❖ Biology of Her-2 positive breast cancer (A)
❖ Regime, interval and duration of therapy and key supporting
trials (A)
❖ Common adverse effects (A)
❖ Evidence of benefit on survival and local, regional and distant
recurrence rates (B)
❖ CD4/6 inhibitors in adjuvant trials (A)
❖ mTOR inhibitors in adjuvant trials (S)
❖ PARP inhibitors in adjuvant trials (S)
❖ Immunotherapies in adjuvant trials (S)
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9.1. Radiation therapy to the breast
❖ Indications and contraindications (B)
❖ Influence on local and regional recurrences on survival (B)
❖ Most common side effects and their management (early and
late, including risk of second cancers including angiosarcoma)
(B)
❖ Partial breast radiation therapy: techniques, indications, con-
traindications, advantages, disadvantages (A)
❖ Interaction with surgery including the effect on wound healing,
breast fibrosis and shrinkage, breast lymphoedema (A)
❖ Radiation therapy and breast reconstruction (A)
❖ Indications for and impact of boost to the primary tumour bed
(A)
❖ Use of marker clips to identify primary tumour bed for boost
volume localization (B)
❖ Impact of Oncoplastic surgery on identification and size esti-
mation for the target volume for radiotherapy boost (A)
❖ Modern fractionation regimes (B)
❖ Modern and alternative irradiation techniques to reduce the
toxicity (IMRT, DIBH, IPRT, prone, lateral)
❖ Awareness of the current research interest in neoadjuvant
radiotherapy in current trials (A)9.2. Radiation therapy to the axilla
❖ Indications and contraindications (B)
❖ Adverse effects in the short and longer term including rates of
lymphoedema (A)
❖ Interactionwith surgery (pedicle fibrosis for subsequent axillary
based pedicle reconstruction), fibrosis (A)
❖ Trial data comparing axillary RT with axillary surgery (A)
❖ Lymphoedema rates (B)9.3. Radiation therapy to the chest wall
❖ Indications and contraindications (B)
❖ Adverse effects in the short and longer term (A)
❖ Interaction with reconstructive surgery (A)
❖ Trial data comparing RT with no RT in terms of local recurrence
rates and survival (A)9.4. Radiation therapy for palliation of locally advanced and
metastatic disease
❖ Indications and contraindications for local and regional radia-
tion therapy (B)
❖ Indications and contraindications for radiation therapy for
distant metastases (B)
❖ Oligometastatic disease: definition; role of locoregional and
metastases-directed radiation therapy (B)
❖ Role of primary radiotherapy in patients who are unfit for sur-
gery (A)10. Breast cancer in special groups
10.1. Breast cancer in young women
❖ Need for and indications for genetic counselling/testing (B)
❖ Imaging limitations in younger women (poor mammographic
sensitivity) (B)
❖ Variation in tumour subtype, stage and biological behaviour (A)
❖ Local, regional and systemic treatment and how these may need
to be modified in younger women (e.g. use of RT boost) (A)
❖ Local, regional and distant recurrence rates in younger women
(A)
❖ Survival variance with age (A)
❖ Fertility, pregnancy and contraception during and after breast
cancer (A)
❖ Breast cancer in pregnancy and how to manage disease in all 3
trimesters (A)
❖ Premature menopause due to breast cancer treatment and how
to manage this, (B)
❖ BRCA associated cancers: presentation, type and management
(A)
❖ Psychological impact (A)10.2. Breast cancer in the elderly
❖ Tailoring local, regional and systemic treatments according to
co-morbidities, frailty, cognitive impairment, polypharmacy and
patient preference (A)
❖ Local, regional and distant recurrence rates in older women (A)
❖ Survival (overall and breast cancer specific) in older women (A)
❖ Treatment morbidity in older age groups (A)
❖ Adapted techniques and fractionation schemes to age and PS10.3. Male breast cancer
❖ Risk factors for male breast cancer (A)
❖ Incidence, age specific incidence and prognosis (A)
❖ Need for genetic counselling/testing (A)
❖ Surgical treatment and how this may differ in males (B)
❖ Adjuvant treatment and how this may differ in males (B)
❖ Local, regional and distant recurrence rates (A)
❖ Survival (A)
❖ Psychological impact (A)10.4. Other breast malignancies-incidence, diagnosis and treatment
modalities
❖ Malignant and borderline phyllodes tumour (A)
❖ Sarcomas: primary and secondary (radiation induced) (A)
❖ Metastases from other malignancies (A)
❖ Lymphoma in the breast or axilla (A)
❖ Breast Implant Associated Anaplastic Large Cell Lymphoma
(BIA-ALCL) (A)
11. Atypias and in situ disease
11.1. Atypias (B3 lesions)
❖ Atypical ductal hyperplasia, atypical lobular hyperplasia, clas-
sical lobular neoplasia in situ (cLCIS), pleomorphic lobular
neoplasia in situ (pLCIS), columnar cell hyperplasia, papilloma,
radial scar: awareness of pathological appearance, diagnostic
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formation (B)
❖ The prevalence of associated in situ or invasive cancer when risk
lesions detected in core needle/vacuum assisted biopsy (B)
❖ Role of vacuum assisted excision (A)
❖ Appropriate indications for surgery in the management of aty-
pias (B)
❖ Concomitant and later breast cancer risk of these lesions (B)
❖ Role of chemoprevention and enhanced screening in risk man-
agement (A)
❖ Risk reducing surgery indications (A)11.2. DCIS
❖ Epidemiology: incidence, risk factors, prognosis (B)
❖ Classification of DCIS (encysted papillary, low, intermediate and
high grade, Paget's) (B)
❖ Pathological criteria for the diagnosis of DCIS (B)
❖ Biological characteristics (ER positive, Her-2 positive, array
based) (A)
❖ Incidence and role of screening. Screen detected versus symp-
tomatic disease characteristics and prognosis (A)
❖ Treatment and prognosis of DCIS (see below in various treat-
ment sections) including surgery, radiotherapy rates of recur-
rence and prognosis (B)
❖ Appropriate margins of resection (B)
❖ Rates of invasive and in situ recurrence and risk factors of
recurrence (B)
❖ DCIS prognostic/risk scores (Van Nuy's, genetic arrays, on line
algorithms) (A)
❖ Debate about over treatment and over-diagnosis in the
screening setting and in the older women. Aware of ongoing
trials (LORIS, LORD, COMET) (A)12. Psychosocial issues and follow-up care. ‘Survivorship’
issues
❖ The need of psychological or social support in women with
newly diagnosed breast cancer and during the entire course of
disease (B)
❖ The role of follow-up care in breast cancer survivors: detecting
recurrences, influence on survival, follow up protocols and
methods (B)
❖ Methods of follow-up and the frequency of follow-up (B)
❖ Conservative and surgical management of lymphoedema (B, A)
❖ Chronic pain and sensory disorders after breast cancer treat-
ment (A)
❖ Endocrine issues in breast cancer survivors, e.g. menopause
symptoms and bone health, especially in the very young patient,
including hot flushes, genitourinary syndrome of the meno-
pause, premature osteoporosis (A). Role of menopausal hor-
mone replacement therapy (systemic or topical vaginal creams)
including risks and benefits (A). Role of menopausal hormone
replacement therapy after risk reducing oophorectomy in BRCA
gene carriers (A)
❖ Depression, anxiety and fear of recurrences (A)
❖ Cognitive disorders (A)
❖ Sexuality including psychosexual and physical issues such as
early menopause/antioestrogen induced loss of libido, depres-
sion, anxiety, loss of confidence due to body image changes,
genitourinary syndrome of the menopause. Awareness of the
above, how to diagnose and manage (A)
❖ Fertility issues and how to manage them (A)13. Benign breast diseases and conditions
13.1. Gynaecomastia
❖ Aetiology (pubertal, obesity, hormonal, alcohol and liver dis-
ease, therapeutic or recreational drug induced, genetic etc) (B)
❖ Assessment of diagnosis and severity (A)
❖ Management (reassurance, removal of underlying cause if
possible, surgery for symmetry, surgery to reduce, liposuction,
en bloc resection techniques, role of drug therapy) (A)13.2. Nipple discharge
❖ Aetiology and presentation (B)
❖ Investigation and assessment (imaging and cytology e accuracy,
sensitivity and specificity) (B)
❖ Role of microdochectomy or total duct excision (B)13.3. Fibrocystic change
❖ Aetiology and presentation (B)
❖ Management (B)13.4. Cyclical and non-cyclical mastalgia
❖ Aetiology and presentation (B)
❖ Management (B)13.5. Breast hypertrophy
❖ Aetiology and incidence (A)
❖ Management strategies (A)13.6. Puerperal and periductal mastitis
❖ Aetiology (B)
❖ Microbiology and antimicrobial therapy (B)
❖ Management (B)13.7. Breast fistula
❖ Aetiology and incidence (B)
❖ Management strategies (B)13.8. Other rare forms of mastitis
❖ Granulomatous mastitis role of clinical history, laboratory tests,
cultures, microscopy in diagnosing the aetiology (B)
❖ Mondor's disease (A)
❖ Lymphocytic lobulitis (A)
❖ Tuberculosis (B)
❖ Plasma cell mastitis (A)
❖ Non-puerperal chronic periductal mastitis and fistula
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❖ Clinical and radiological features (e.g. Stavros' criteria), in-
dications for biopsy (B)
❖ Natural history variant (tubular adenoma, juvenile fibroade-
noma, lactating adenoma, myxoid fibroadenoma) and analogue
(benign lesions with similar clinical and/or imaging features:
nodular pseudoangiomatous hyperplasia, hamartoma) lesions;
differences from (benign) phyllodes tumour (A)
❖ Management (A)13.10. Benign phyllodes tumour
❖ Clinical, pathological and radiological features (B)
❖ Natural history (B)
❖ Management (B)13.11. Macrocysts (simple, complicated, and complex)
❖ Aetiology, incidence and presentation (B)
❖ Management of simple cysts and risk factors for underlying
malignant pathology (B)13.12. Papilloma
❖ Multiple papilloma: association with nipple bleeding and
discharge, increased risk of malignancy (A)
❖ Single papilloma: symptoms and signs, management (B)
❖ Papillary lesions (the morphologic spectrum and main differ-
ential diagnostic features: papillomas vs encapsulated papillary
carcinoma, solid papillary carcinoma) (A)14. Aesthetic breast surgery, breast implants and other
medical implantable devices/materials
14.1. Breast implants
❖ Implant types: silicone, saline, polyurethane, surface (smooth or
textured), round or anatomic shape, expandable or fixed volume
(A)
❖ Capsule formation: presentation, rates with time, risk factors,
classification (Baker), investigation, management (A)
❖ Rupture: presentation, rates with time, variation by implant
type, causes, classification (intracapsular, extracapsular),
adverse effects, investigation, management (A)
❖ Extrusion: presentation, rates with time, risk factors, manage-
ment (A)
❖ Malposition: Assessment, management strategies. (A)
❖ Breast Implant Associated Anaplastic Large Cell Lymphoma (BI-
ALCL): risk factors, incidence, presentation, diagnostic evalua-
tion, management and prognosis (A)
❖ Implant surgery: indications, contraindications, preparatory
work up, choice of incision, choice of implant type, choice of
implant position. (A)
❖ Outcomes: short, medium and long term adverse events and
patient satisfaction (A)
❖ Psychological issues related to breast aesthetics and augmen-
tation (A)14.2. Breast reduction and mammoplasty
❖ Indications, contraindications and risk factors for adverse out-
comes (A)
❖ Techniques (pros and cons, specific indications for different
techniques (A)
❖ Technical aspects of surgery and aftercare (A)
❖ Outcomes: short medium and long term complications and
patient satisfaction (A)
❖ Impact on breast feeding and nipple sensation (A)14.3. Acellular dermal matrices and implantable meshes
❖ Different types of material properties and handling character-
istics: plastic mesh versus biological material (xenograpft,
allograft) (A)
❖ Indications, contraindications (A)
❖ Safety and approvals. (A)
❖ Complications: rates and risk factors. Long term outcomes (A)
❖ Technical aspects of use: selection of technique, risks associated
with individual techniques, risk factors for adverse outcomes (A)
❖ Placement (sub-pectoral sling versus pre-pectoral pocket). (A)
❖ Revision surgery techniques (A)
❖ Interaction with radiotherapy (A)14.4. Autologous fat grafting
❖ Techniques and theoretical basis (A)
❖ Oncological and medical safety (A)
❖ Donor site and recipient site morbidity (A)
❖ Indications and contraindications (A)
❖ Pre-operative preparation and counselling (A)
❖ Aftercare (A)
15. Advanced breast cancer
15.1. Locally advanced
❖ The definition of locally advanced breast cancer (B)
❖ Primary systemic treatment in locally advanced breast cancer
(endocrine, chemotherapy and targeted treatments) (A)
❖ Management of neoadjuvant (baseline scans and monitoring
response, MRI), use of marker clips (A)
❖ Timing of axillary surgery (A)
❖ Inflammatory breast cancer (diagnosis, prognosis, manage-
ment) (B)
❖ Surgery in patients with locally advanced breast cancer (A)
❖ The role of radiotherapy in locally advanced breast cancer (A)
❖ Response rates after primary chemotherapy (NAC) by tumour
subtype (A)
❖ Extent of surgery after partial or complete pathological response
(A)
❖ Pathological classification of response (A)
❖ Local recurrence rates after conservation surgery post NAC (A)
❖ Survival rates comparing primary chemotherapy (NAC) and
adjuvant chemotherapy (A)15.2. Treatment of disseminated (stage IV) breast cancer
❖ Palliative surgical procedures in disseminated (stage IV) cancer,
for example palliative mastectomy, treatment and prevention of
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into liver resection in oligometastatic disease. (A)
❖ Removal of primary tumour in disseminated breast cancer-
influence on survival (A)
❖ The oligometastatic disease e cure intent (A)
❖ Removal of liver or pulmonary metastases-influence on survival
(A)
❖ The role palliative radiotherapy in disseminated breast cancer
(B)
❖ Palliative treatments to relieve symptoms like pain and nausea
(B)
❖ Social, psychological and spiritual support in patients with
disseminated breast cancer (B)
❖ Management of cerebral metastatic disease: steroids, stereo-
tactic radiosurgery, gamma knife, surgery, whole brain RT, sys-
temic therapies (S).15.3. Systemic agents used in the advanced setting
❖ Chemotherapy (A)
❖ Antioestrogens (A) (SERMs, aromatase inhibitors)
❖ CD4/6 inhibitors (A),
❖ Fulvestrant (A)
❖ Denosumab (A)
❖ GCSF (A)
❖ Immunotherapy (A)
❖ PARP inhibitors (A)
❖ mTOR inhibitors (A)
❖ Her-2 targeted agents (A)
❖ Analgesia, anti-emesis (B)
16. Research and evidence based medicine
❖ The p-value and the use of confidence intervals and their rela-
tion to the sample size; the importance of power analysis and
sample size calculation in trials (B)
❖ The difference between statistical and clinical significance (B)
❖ Types of bias and how to avoid them (B)
❖ Prospective and retrospective study setting (B)
❖ Study settings (randomized, prospective non-randomized, case-
control, retrospective etc) (B)
❖ Definitions of phase I, phase II, phase III and phase IV trials (B)
❖ Definitions of absolute and relative risk reduction or advantage
(B)
❖ Levels of evidence and how these influence treatment recom-
mendations (B)17. Practical knowledge and skills curriculum
The following is a list of the practical skills that are required of a
fully trained breast surgeon. Acquisition of these skills is estimated
to take 2 years of full time training (for someonewith basic general,
gynaecological or plastic surgery competencies) and is divided into
a number of discrete subject areas. Ideally candidates should spend
time within multidisciplinary specialist disciplines (such as radi-
ology, pathology, oncology) to achieve a full range of competencies
but it is accepted that this may not be possible.
The candidates must keep a logbook, signed off by their trainer,
of the operations they have attended as an assistant or operations
they have carried out, supervised or unsupervised, and also of the
clinics they have attended and the multidisciplinary meetings they
have attended.17.1. Radiology
Candidates should spend some time observing and learning
about a range of procedures listed below:
❖ Breast imaging and percutaneous needle biopsies:
❖ Counsel patients regarding breast imaging methods and
percutaneous needle biopsies: Indications, limitations and how
these are performed
❖ Evaluate mammograms, ultrasound imaging and breast MRIs
❖ Perform core needle biopsy and punch biopsy (Fine needle bi-
opsy is rarely used but may also be of value in some settings and
centres)
❖ Knowledge regarding preoperative and postoperative staging by
imaging:
❖ Indications, limitations and how these are performed
❖ Knowledge of axillary staging, US imaging of nodes and in-
dications for biopsy
❖ Understand diagnostic staging: indications for CT imaging, bone
scans, CT-PET in different breast cancer stages. Ability to inter-
pret images at a basic level.
LOG BOOK:
Manage cases and review:
8 screening mammograms.
20 diagnostic/symptomatic mammograms.
10 breast MRIs.
Breast ultrasound: 15 (hands on) or 30 (observation only).
Percutaneous procedures: 30 including cyst aspiration, percu-
taneous core needle sampling, palpation or image guided, seroma
aspiration with/without drain placement, percutaneous abscess
drainage with/without drain placement.
17.2. Pathology
Candidates should follow specimens through pathology to un-
derstand specimen marking, cut up and processing to optimise
their collaboration with pathology.
❖ Understand handling and different techniques for breast path-
ologic analysis (Frozen section, routine staining,
immunohistochemistry)
❖ Knowledge about tumour margin assessment
❖ Nodal evaluation
❖ Sentinel lymph node
o Nodal dissection specimens
❖ Pathologic staging of tumours
❖ Intraoperative analysis
LOG BOOK: Observe or discuss with a pathologist.
8 cancer case sign outs.
(8 frozen or intraoperative evaluations, may not be applicable in
all units).
8 benign and/or high risk lesions.
17.3. Clinical session types
❖ Participate in results clinics including ‘breaking bad news’ and
initial therapy decision-making
❖ Participate in preoperative clinics including oncoplastic/recon-
structive clinics
❖ Participate in breast cancerespecific operating lists
❖ Participate in diagnostic clinics for both benign and malignant
diseases
❖ Participate in screening clinics
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ideally jointly with plastic surgeons or surgeons who undertake
primary reconstruction
❖ Participate in familial risk assessment clinics
❖ Participate in postoperative clinics (assessing wound healing,
primary aesthetic outcome and recovery from surgery, is further
surgery required, or follow-up etc)
❖ Note: it is not expected that special clinics will exist for all of the
above, but the clinics attended should offer the above as part of
their remit (i.e. may be a generic breast clinic at which results
are given or diagnostic tests performed etc).17.4. Surgical management of the breast and axilla
❖ Diagnostic excisional biopsy, with/without wire/seed/ultra-
sound localization
❖ Central/Major/Terminal duct exploration and excision
❖ Breast conservative surgery with/without image-guided locali-
zation (wire/seed/ultrasound/magnetic)
❖ Oncoplastic breast conservative surgery-level I and II techniques
❖ Mastectomy:
- Total mastectomy
- Skin-sparing mastectomy
- Nipple/areolar sparing mastectomy(Candidates should understand the techniques to ensure skin
viability: careful plane dissection, careful tissue handling,
high risk individuals where extra care is required such as
smokers, diabetics and the obese, novel techniques for skin
viability assessment, use of PICO/vac dressings in high risk
cases)❖ Lymph Node excision
❖ Axillary sentinel node biopsy using a recognised technique such
as:
- Blue dye
- Radioisotope
- Both
- Other techniques for SLN (magnetic, iodine seed, US localiza-
tion, indocyanine green)
❖ Axillary node dissection
❖ Breast asymmetry after breast conservation
❖ Awareness of the management techniques for repair of chest
wall defects following resection of locally advanced breast
cancer (it is accepted that these procedures are rare and direct
experience may be difficult to obtain).
❖ Lymphoedema prevention and treatment17.5. Surgical management after neoadjuvant treatments
❖ Indications for neoadjuvant systemic therapy, specifically with
regards to optimisation of breast conserving therapy
❖ Breast conservative surgery with/without imaging guided
support
❖ Targeted excision of axillary clipped node (guided by seed, wire,
ultrasound, magnetic marker)17.6. Surgical management/counselling for genetic syndromes
❖ Family history clinic attendance and skills in performing risk
assessment (use of risk assessment tools such as IBIS II etc) and
counselling
❖ Understanding of the surgical, screening and other risk man-
agement options for:❖ BRCA 1
❖ BRCA 2
❖ P53 mutations (Li Fraumeni)
❖ Cowden's syndrome
❖ PALB2
❖ CHEK 2
❖ Knowledge of other panels
LOG BOOK
1. Must have attended at least 5 genetic/familial risk assessment
clinics
2. Must have followed through at least 5 risk reduction cases as
they undergo counselling and surgery (and be signed off as such
by their trainer).17.7. Reconstruction techniques
❖ Tissue expander placement
❖ Use of acellular dermal matrices or other biological or non
biological meshes
❖ Permanent silicone implant placement
❖ Pedicle flaps for breast reconstruction:
- Latissimus dorsi
- TRAM
❖ Mastopexy for symmetry
❖ Therapeutic mammoplasty
❖ Fat grafting and lipofilling
❖ Nipple grafting
❖ Nipple reconstruction
❖ Autologous free flaps (observation only)
❖ Revision procedures following on from the above
LOG BOOK:
1. Attended at least 40 regular, at least weekly, pre- and post-
surgical multidisciplinary case management meetings
2. Attended at least 70 outpatient clinics during a regular 1e2 year
work on a surgical unit with at least 150 primary breast cancer
cases a year, according to the local organization practise,
including:
A. Diagnostic, preoperative and postoperative clinics
B. Clinics with the radiation/medical/clinical oncologist at
which the decisions on adjuvant and neoadjuvant therapy
are made.
C. Follow-up clinics at which the side-effects of surgery and
radiation can be assessed
D. Clinics at which the management of women with advanced
disease (both locally advanced and metastatic) takes place
E. Genetic/family historic clinics, in which women at risk are
advised
F. Clinics at with oncoplastic and reconstructive counselling
and planning are made
3. Personally performed or assisted as follows
Personally performed
 at least 40 operations on benign or borderline lesions
 at least 80 full axillary lymph node dissections or sentinel node
biopsies, including
- at least 30 full ALND
- at least 30 SNB
 at least 100 breast cancer operations, including:
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oncoplastic level I - II breast remodelling procedures
 at least 40 mastectomies, including at least 10 NAC- or skin-
sparing mastectomies
Assisted or observed:
 at least 5 observed or assisted oncoplastic level II breast
remodelling procedures
 observed or assisted at 10 immediate and delayed total breast
reconstructions using both implants and autologous tissue.17.8. Medical oncology
Candidates should attend some medical oncology clinics during
their training to gain insight into the following:
❖ Management of common complications of chemotherapy
administration
❖ Use of gene signatures to direct systemic treatment
recommendations
❖ Management of hormone receptor positive breast cancers (early
and late stage)
❖ Management of hormone receptor negative breast cancers
❖ Management of Her2 positive breast cancers
❖ Management of cancers by stage:T stage
Node negative
Node positive❖ Systemic treatment for the de novo stage 4 patient
LOG BOOK
Observe: 5 new adjuvant chemotherapy for early breast cancer
consultations by oncologists.
Observe: 5 new adjuvant radiotherapy for early breast cancer
consultations by oncologists.
Observe: 5 new recurrent or metastatic disease consultations by
oncologists.
Observe: 5 Follow up visits during oncology treatment.
Observe: 2 new consultations relating to fertility preservation in
women about to commence breast cancer therapy.
Manage secondary effects of breast cancer therapy including:
Lymphoedema, acute radiation dermatitis, genitourinary syn-
drome of the menopause, depression, hot flushes.
17.9. Radiation oncology
Candidates should attend some radiation oncology clinics and
radiotherapy planning sessions to give them insight into the
following:
❖ Radiation biology principles
❖ Radiotherapy indications and contraindications:
- Breast conservation: Whole breast radiation
(hypofractionated)
- Post-mastectomy radiation
- Regional radiotherapy
- Primary radiotherapy
❖ Management of common radiation complications
- Acute radiation dermatitis, including use of steroid creams
and routine skin health measures
- Lymphoedema
- Chronic fibrosis
- Interaction with implants- Secondary cancers (lung, angiosarcoma)
- Poor wound healing
❖ Partial breast radiation techniques:
- Interstitial brachytherapy
- External beam partial breast
- Intraoperative radiation therapy
❖ Radiation therapy for metastatic disease:
- Distant Treatment
- Palliation
LOG BOOK
15 new breast cancer consultations to discuss RT.
5 observations of radiotherapy administration and planning
sessions.
15 f/u visits after radiotherapy treatment.
(10 partial breast irradiation (brachytherapy and or intra-
operative RDT) if available).18. Research
Candidates must have a basic ability to critically appraise evi-
dence based research so they may incorporate new findings into
clinical practice and keep up to date. BRESO is aware that under-
taking primary research is not possible for all surgeons but a basic
level of knowledge is required to keep skills and practices up to
date. The following is a recommended knowledge and skills base:
❖ Protection of Human Subjects: understanding of the ethical and
legislative framework relevant to the conduct of research
❖ Inclusion of diverse study populations
❖ Basic Statistical Analysis such as understandingmeans, medians,
standard deviation, and simple comparative statistics.
❖ Institutional Review (Ethics committee) Board process and
application
❖ Critical Evaluation of Study Design
❖ Assessment of Clinical Trial, Defining levels of Evidence/meta-
analysis
❖ Defining study populations, sample size, power
❖ Basic Survival Analysis
❖ Assessment of Health Related QOL
❖ Fundamentals of Health Outcomes Studies
CV requirements: To have presented an audit or other piece or
research or service evaluation at a local, national or international
meeting as evidence of research engagement.19. Communication skills
Good communication using lay terminology and expressed with
empathy and sensitivity is key to good breast care. Candidates
should understand the concept of shared decisionmaking and have
the skills to be able to support this in their practice.
Formal attendance at a communication skills workshop is best
practice but may not be readily available.
❖ Communication with and education of the non-medical com-
munity (patients and patient groups, managers, students, other
professional colleagues)
❖ Communication and interaction with patients, in particular
breaking bad news, treatment counselling, risk counselling and
skills in identification of anxiety and depression
❖ Communication and interaction with cancer support groups
❖ Communication with and education of non-oncologic
physicians
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screening, diagnostic tests, and treatments of cancer
❖ Able to identify patients who may benefit from formal psycho-
logical support and where this may be accessed locally20. Optional module-autologous tissue transfer-aesthetic
breast surgery
❖ Free or pedicled or perforator flaps for breast reconstruction:
o DIEP
o Gluteal
o TUG
o LD
o Perforator flaps or various types
❖ Cosmetic breast surgery
o Breast augmentation
o Cosmetic breast reduction (benign)
o Revision augmentation
o Counselling for cosmetic procedures21. Additional training
Requirements include:
1. Attend two international breast cancer congress during training
2. Attend 2 international breast cancer educational courses
3. Work in a Unit with a properly constituted MDT22. Approval criteria for tier 2 training centres
The training process for highly specialised breast cancer pro-
fessionals, in particular breast cancer surgeons, equipped with the
mandatory multidisciplinary knowledge and skills for modern
breast cancer care, must be carried out in high quality, certified
breast cancer centres.
Many hospitals claim to have specialist breast cancer services
but it is known that only a few are well organized into Multidisci-
plinary Specialised Breast Cancer Units and the quality of each in-
dividual service remains often uncertain.
For this reasons training institutions to be in linewith the BRESO
project should fulfill the following minimal requirements in order
to enable fellows to acquire advanced knowledge and skills in the
surgical and multidisciplinary management of breast cancer:
1. Being accredited as a Certified Breast Center by an International
Quality Certification process such as the EUSOMA or equivalent
(e.g. German DKG/DGS); considering the inhomogeneous dis-
tribution of quality assurance initiatives across European terri-
tories, as an alternative some form of Quality Certification at
national level can be accepted provided that is characterized by
a process of accreditation based on fulfillments of mandatory
requirements and continuing audit by third parties.
Such National Certification systems, to be considered in line
with the project, must include mandatory requirements in
terms of:
- Critical mass of at least 150 new cases/year per 250.000
inhabitants.
- Core team, which should meet specific requirements in terms
of composition and specialist training of its members
- Clinical lead
- Multidisciplinary case managements meetings
- Protocols- Data management and quality assurance
- Internal and external auditing
- Facilities/services/clinics
- Screening program
- Associated services and personnel
- Information to patients and waiting time
- Collaboration with patient's representatives
- Research activity
- Continuing education program
- Teaching
Once a unified quality certification program, according to in-
ternational standards for certification bodies, will be set in place
across Europe, this will become the only mandatory certification
required for an Institution to be accredited as Breast Surgery
Training Center.
2. Being based on multidisciplinary training and multidisci-
plinary care.The role of the breast surgeon has changed and requires a
clear understanding of the complex interactions among the
different specialties involved in multidisciplinary approach
to breast cancer management.
The core team members of an accredited training centres for
BC specialists, besides reaching the minimum standards in
terms of number of treatments provided and time spent in
the field of breast cancer, must also demonstrate to have
gone through a dedicated specialist multidisciplinary
training and multidisciplinary working experience.
Multidisciplinary team working requires complex in-
teractions and collaborations between specialists, who not
only have to work with a common purpose but must have
gone through specific training that goes beyond that of the
specialty of origin, ensuring an overlap of knowledge. Each
specialist must be aware of the working field of his/her col-
leagues and the most important aspects of the scientific
evidence in those fields. Only this way he/she will be able to
sit at the multidisciplinary table contributing with informed
opinions to make aware therapeutic indications through a
critical discussion.
An accredited breast surgery training center must organize
rotations for the trainees in all fields of breast cancer care, in
order to allow the development of the necessary across-the-
board knowledge and acquisition of all the management
strategies to ensure optimal patient care.3. Be part of an international network of referral clinical centres
exclusively dedicated to the diagnosis and treatment of breast
cancer (e.g. Breast Center Network).Such networking promotes interactions, collaborations and
benchmarking activities improving breast cancer care and
allowing connections among specialist working in the field.
An accredited training center must offer the trainees op-
portunities for further international working experiences
and collaborations.
A directory of specialist breast units offers relevant infor-
mation on centres with specific expertise in diagnosis, state-
of-the-art treatment, and care of breast cancer in an attempt
to broadcast international standards for multidisciplinary
breast cancer care and to allow breast cancer patients to get
easier access to fully equipped, quality assured, competent
and comprehensive care.4. Academic endorsement:
Either as a University Hospital or through an academic
affiliation the accredited training center must be recognised
academically and issue a certificate at the end of the training
module.
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should be such that students' rotations are in place, giving
the breast surgery trainee the opportunity for practical and
theoretical teaching activity.5. Demonstrate to contribute to the continuous education of staff
members through the implementation of research and educa-
tional programs.During the attendance of a practical module, the trainee
must have the opportunity to participate in multiple teach-
ing conferences internally organized throughout the year at
the training Institution, some examples of which are listed
here
 Breast Education Conferences
 Multidisciplinary Care Conferences
 Breast Cancer Clinical Research Update/Journal Clubs
 Yearly Institutional breast cancer meeting with national or
international relevanceWhenwe try todefine theminimal requirements for standardized
level of training, expertise and practice across Europe, we must keep
inmind we are aiming at defining a program that can be undertaken
all across Europe and must be suitable for different realities.
The course should be organized in modules that can be
completed over time, not necessarily in one single center, but even
in different accredited institution across Europe.
This should ease the attendance of those professionals who have
been practicing for a long time and are caught up in everyday
clinical practice (probably not capable to undergo a true fellowship
program with the duration of 1 or 2 years) minimizing working
leaves, expenditures and travelling.
We are not trying to develop the Breast-SUPER-surgeon, who is
capable of everything and stands alone in the O.R., but the aim
should rather be to obtain solid basic knowledge in all fields of
breast cancer care and develop good practice in fundamental sur-
gical techniques (conventional and oncoplastic). The breast sur-
geon should demonstrate an “across the board” preparation and
capacity to sit at the MDM table, having the required multidisci-
plinary knowledge and skills.
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